Project Grant R01CA304753
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $707K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
- Federal Grant Award Summary Health Research, Inc. (Roswell Park Division) received a $719,951 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded June 2, 2026, with a completion date of May 31, 2031. The grant funds fundamental cancer biology research investigating mechanisms underlying lung cancer lineage plasticity that facilitate adaptation and resistance to targeted therapy. The research specifically addresses how lung...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park Division received a $446,112 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on July 3, 2026, with an ultimate completion date of June 30, 2028. The award funds fundamental cancer biology research focused on identifying age-regulating breast cancer dormancy genes. The research employs Caenorhabditis elegans (C. elegans) dauer models as a novel screening...
- Federal Grant Award Summary Health Research, Inc. at Roswell Park Comprehensive Cancer Center received a $639,379 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded May 1, 2026, with a completion date of April 30, 2031. This award supports the development and characterization of neuroendocrine bladder carcinoma (NEBC) models to advance understanding of disease pathogenesis and improve chemotherapy response outcomes. The project...
- Federal Grant Award Summary Health Research, Inc. (operating as Health Research at Roswell Park) received a $173,500 Project Grant awarded August 7, 2025, by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to conduct a correlative clinical study investigating the effects of CXCR1/2 inhibition on the immune microenvironment of multiple myeloma patients. The research leverages preliminary findings demonstrating significant accumulation of CXCR2-positive...
- Federal Project Grant Award Summary Health Research, Inc. at Roswell Park (doing business as Health Research At Roswell Park) received a $713,312 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2026 through May 31, 2031. The funded research project investigates the impacts of body composition and physical activity on anti-tumor immunity and cancer control in high-grade serous ovarian carcinoma...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 effective June 1, 2026, with completion targeted for May 31, 2028. This award supports research into fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project leverages...
- Federal Grant Award Summary The National Cancer Institute awarded Boston Children's Hospital a $578,559 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on the tumor suppressor function of P190 RhoGAP. The research program investigates how the ARHGAP35 gene product P190A regulates cell proliferation and survival through the Hippo signaling pathway, with particular focus on understanding how...